Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 2.6 USD 7.44%
Market Cap: $499.4m

Cerus Corp
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cerus Corp
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Other Items
-$8.7m
CAGR 3-Years
39%
CAGR 5-Years
28%
CAGR 10-Years
10%
Haemonetics Corp
NYSE:HAE
Other Items
$6.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ICU Medical Inc
NASDAQ:ICUI
Other Items
$211.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
18%
Align Technology Inc
NASDAQ:ALGN
Other Items
-$41m
CAGR 3-Years
N/A
CAGR 5-Years
12%
CAGR 10-Years
10%
Lantheus Holdings Inc
NASDAQ:LNTH
Other Items
-$578.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Other Items
-$347.7m
CAGR 3-Years
-198%
CAGR 5-Years
N/A
CAGR 10-Years
-44%
No Stocks Found

Cerus Corp
Glance View

Market Cap
499.4m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
0.93 USD
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Cerus Corp's Other Items?
Other Items
-8.7m USD

Based on the financial report for Sep 30, 2025, Cerus Corp's Other Items amounts to -8.7m USD.

What is Cerus Corp's Other Items growth rate?
Other Items CAGR 10Y
10%

The average annual Other Items growth rates for Cerus Corp have been 39% over the past three years , 28% over the past five years , and 10% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett